[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2112838T3 - Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. - Google Patents

Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.

Info

Publication number
ES2112838T3
ES2112838T3 ES90911332T ES90911332T ES2112838T3 ES 2112838 T3 ES2112838 T3 ES 2112838T3 ES 90911332 T ES90911332 T ES 90911332T ES 90911332 T ES90911332 T ES 90911332T ES 2112838 T3 ES2112838 T3 ES 2112838T3
Authority
ES
Spain
Prior art keywords
cell receptor
autoimmune
therapeutic agents
tcr
malignant diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911332T
Other languages
English (en)
Other versions
ES2112838T5 (es
Inventor
Corporation Connetics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27009922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2112838(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2112838T3 publication Critical patent/ES2112838T3/es
Application granted granted Critical
Publication of ES2112838T5 publication Critical patent/ES2112838T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN PEPTIDOS Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN PEPTIDOS INMUNOGENICOS DE UN RECEPTOR DE CELULAS T MARCADOR (TCR) CARACTERISTICOS DE UNA ENFERMEDAD RELACIONADA CON EL SISTEMA INMUNE, CAPACES DE PREVENIR, SUPRIMIR O TRATAR LA ENFERMEDAD. EN UN ASPECTO PREFERENTE DE LA INVENCION, LA SECUENCIA AMINOACIDA DEL PEPTIDO CORRESPONDE A AL MENOS PARTE DE UNA REGION DETERMINADORA COMPLEMENTARIA (CDR) O A UNA REGION HIPERVARIABLE DEL TCR. TAMBIEN SE PRESENTAN ANTICUERPOS Y/O CELULAS T INMUNOLOGICAMENTE REACTIVAS AL PEPTIDO DEL TCR CAPACES DE PREVENIR, SUPRIMIR O TRATAR UNA ENFERMEDAD RELACIONADA CON EL SISTEMA INMUNE MEDIANTE UNA TRANSFERENCIA PASIVA.
ES90911332T 1989-07-19 1990-07-19 Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. Expired - Lifetime ES2112838T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38280489A 1989-07-19 1989-07-19
US382804 1989-07-19
US46757790A 1990-01-19 1990-01-19
US467577 1990-01-19

Publications (2)

Publication Number Publication Date
ES2112838T3 true ES2112838T3 (es) 1998-04-16
ES2112838T5 ES2112838T5 (es) 2004-09-01

Family

ID=27009922

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911332T Expired - Lifetime ES2112838T5 (es) 1989-07-19 1990-07-19 Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.

Country Status (13)

Country Link
EP (1) EP0552142B2 (es)
JP (1) JP3072330B2 (es)
KR (1) KR100216097B1 (es)
AT (1) ATE161850T1 (es)
AU (1) AU652540B2 (es)
CA (1) CA2064077C (es)
DE (1) DE69031919T3 (es)
DK (1) DK0552142T3 (es)
ES (1) ES2112838T5 (es)
IL (1) IL95125A (es)
NO (1) NO920252L (es)
NZ (1) NZ234586A (es)
WO (1) WO1991001133A1 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US6413516B1 (en) * 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US6007815A (en) * 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
JPH05506995A (ja) 1990-05-01 1993-10-14 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 疾患関連マーカーとしてのt細胞レセプター可変トランスクリプト
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ イミューン レスポンス コーポレイション 特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
AU674494B2 (en) * 1991-05-31 1997-01-02 Xoma Corporation T cell receptor peptides as therapeutics for immune-related disease
WO1993004695A1 (en) * 1991-08-28 1993-03-18 The Wistar Institute T cell receptor-based therapy for rheumatoid arthritis
WO1993006135A1 (en) * 1991-09-23 1993-04-01 Genentech, Inc. Diagnosing and treating autoimmune disorders
CA2126686A1 (en) * 1991-12-24 1993-07-08 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
WO1995023164A1 (en) * 1994-02-23 1995-08-31 Akzo Nobel N.V. A t cell receptor sequence specifically associated with an immune disease
DE4408999A1 (de) * 1994-03-16 1995-09-28 Braun Melsungen Ag Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus
GB9423085D0 (en) * 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック ファーマスーティカルズ コーポレイション 非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
PL373835A1 (en) 2001-01-31 2005-09-19 Biogen Idec Inc. Use of cd23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7250552B2 (en) 2001-06-07 2007-07-31 Pioneer Hi-Bred International, Inc. QTL controlling sclerotinia stem rot resistance in soybean
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
KR101092171B1 (ko) 2003-04-09 2011-12-13 제넨테크, 인크. Tnf-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
EP3130349A1 (en) 2004-06-04 2017-02-15 Genentech, Inc. Method for treating multiple sclerosis
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
EP1869076A2 (en) 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
US8034902B2 (en) 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008137915A2 (en) 2007-05-07 2008-11-13 Medimmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3025714B9 (en) 2007-09-14 2020-11-18 Biogen MA Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
KR101361905B1 (ko) 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX2011010159A (es) 2009-04-02 2011-10-17 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
US20110027275A1 (en) 2009-07-31 2011-02-03 Napoleone Ferrara Inhibition of tumor metastasis
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AU2010297344A1 (en) 2009-09-17 2012-02-23 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
JP2013541594A (ja) 2010-11-08 2013-11-14 ジェネンテック, インコーポレイテッド 皮下投与される抗il−6受容体抗体
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
KR101913448B1 (ko) 2011-02-04 2018-10-30 제넨테크, 인크. Fc 변이체 및 그의 생산 방법
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ige抗體及其使用方法
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
NZ628126A (en) 2012-02-16 2016-10-28 Atyr Pharma Inc Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
BR112014032193A2 (pt) 2012-06-27 2017-06-27 Hoffmann La Roche métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
ES2738305T3 (es) 2012-10-05 2020-01-21 Hoffmann La Roche Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
CA2901126C (en) 2013-02-25 2022-01-25 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
WO2014151517A1 (en) 2013-03-15 2014-09-25 Intermune, Inc. Methods of improving microvascular integrity
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
EP3122377A4 (en) 2014-03-27 2018-03-14 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
EA201790569A1 (ru) 2014-09-12 2017-08-31 Дженентек, Инк. Антитела и иммуноконъюгаты против cll-1
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
RS59203B1 (sr) 2014-12-05 2019-10-31 Hoffmann La Roche Anti-cd79b antitela i postupci primene
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック, インコーポレイテッド 抗cll-1抗体及び使用方法
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
TWI747843B (zh) 2015-10-02 2021-12-01 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
KR20240107346A (ko) 2015-10-06 2024-07-09 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
BR112018010945A2 (pt) 2015-12-30 2018-12-04 Genentech Inc formulações com degradação de polissorbato reduzida
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3551050A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US20190343425A1 (en) 2016-12-14 2019-11-14 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2018112255A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
CN110072551B (zh) 2016-12-14 2023-05-23 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
US11033490B2 (en) 2016-12-14 2021-06-15 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
CA3045472A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
US20210401895A1 (en) 2017-03-30 2021-12-30 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US20210128667A1 (en) 2017-08-23 2021-05-06 Kezar Life Sciences Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
JP7421504B2 (ja) 2018-06-01 2024-01-24 ビオラ・セラピューティクス・インコーポレイテッド 胃腸のマイクロバイオームの検出および操作のためのデバイスおよびシステム
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3115110A1 (en) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN112805026A (zh) 2019-02-06 2021-05-14 桑格摩生物治疗股份有限公司 用于治疗i型黏多糖贮积症的方法
CN113939586A (zh) 2019-04-02 2022-01-14 桑格摩生物治疗股份有限公司 治疗β-地中海贫血症的方法
CN110747267A (zh) * 2019-10-18 2020-02-04 佛山市第一人民医院(中山大学附属佛山医院) 一种用于判断临床治疗对膜性肾病疗效的标志物
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202330613A (zh) 2021-11-12 2023-08-01 美商建南德克公司 使用整聯蛋白β7拮抗劑治療克隆氏病之方法
WO2024127332A1 (en) 2022-12-14 2024-06-20 Pheon Therapeutics Ltd Cytotoxic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855634T2 (de) * 1987-06-23 1997-02-27 Univ Leland Stanford Junior Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
FI891226A (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.

Also Published As

Publication number Publication date
EP0552142A1 (en) 1993-07-28
CA2064077A1 (en) 1991-01-20
NO920252D0 (no) 1992-01-20
IL95125A (en) 1995-07-31
AU652540B2 (en) 1994-09-01
DK0552142T3 (da) 1998-09-07
AU6048590A (en) 1991-02-22
JP3072330B2 (ja) 2000-07-31
ATE161850T1 (de) 1998-01-15
IL95125A0 (en) 1991-06-10
NZ234586A (en) 1993-02-25
WO1991001133A1 (en) 1991-02-07
JPH05504939A (ja) 1993-07-29
CA2064077C (en) 2002-03-12
EP0552142B1 (en) 1998-01-07
DE69031919D1 (de) 1998-02-12
DE69031919T2 (de) 1998-07-30
NO920252L (no) 1992-03-11
KR100216097B1 (ko) 1999-08-16
EP0552142B2 (en) 2003-12-17
EP0552142A4 (en) 1992-12-30
ES2112838T5 (es) 2004-09-01
DE69031919T3 (de) 2005-01-27
KR920703036A (ko) 1992-12-17

Similar Documents

Publication Publication Date Title
ES2112838T3 (es) Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
DE69230612D1 (de) T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
Lampson et al. Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon.
Garotta et al. Human interferon-gamma receptor. Mapping of epitopes recognized by neutralizing antibodies using native and recombinant receptor proteins.
Olsson et al. Natural polyclonality of spontaneous AKR leukemia and its consequences for so-called specific immunotherapy
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE3262006D1 (en) Radiolabelled peptides derived from crosslinked fibrin for locating thrombi and injectable compositions thereof
KR940007179A (ko) 시디40 (cd40)을 위한 수용성 리간드
PL323626A1 (en) Modified/chimeric superantigenes and their application
DE68925226D1 (de) Monoklonale Antikörper
Wilkinson et al. Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol. Transfer of tolerance by T cells and by T cell extracts.
DE69533464D1 (de) Verfahren zur Herstellung von rekombinanten menschlichen LH-RH Rezeptor Proteinen in spezifischen CHO Zellinien.
RU97101876A (ru) Белки из печени млекопитающих и их использование в онкологии
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
NZ225167A (en) Immunosuppresive peptides (minimum 9 residues)
DK424387A (da) Humant placenta angiogen faktor, der er i stand til at stimulere syntesen af papillaer endothelial celleprotease, dna syntese og vandring
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
Chavin Membrane associated immunoglobulin in pig thymocytes
Waghe et al. Demonstration of a Wilms' tumour associated antigen using xenogenic antiserum.(Preliminary communication)
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
US4707356A (en) Synthetic peptide-based anti-rabies compositions and methods
PyhäLä Neutralizing antibodies against human leukocyte, lymphoblastoid and fibroblast interferons elicited by immunization with human leukocyte interferon
Hauptman et al. A New Protein: Macromolecuiar Insoluble Cold Globulin (MICG) Derived from Mouse Thymocytes
Neveu et al. Stimulation and inhibition of mitogen-induced lymphoproliferation by serum fractions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552142

Country of ref document: ES